TORONTO, March 12 /PRNewswire/ - Meditor Pharmaceuticals Ltd (Trading as M20.F) is pleased to announce it has concluded a merger agreement with AMERICAN MEDICAL TECHNOLOGIES, INC. (AMT).
AMERICAN MEDICAL TECHNOLOGIES, INC. is a U.S. based company which performs biomedical research dedicated to the development and commercialization of proprietary Blood Cell Morphometric Method (BCMM) technology. Its purpose is to detect early cancer in patients where traditional methods do not work.
As a result of the continuous scientific research activity since 1985 a comprehensive Patent was filed in Russia for a "Method for diagnosing human tumor disorders".
Our method, which has already proved to be beneficial to hundreds of patients, reduces the risk for the planned clinical trials and shortens the time to the market. Upon the completion of the automatic analysis and before all the clinical trials are completed, our technology can be applied to many countries and has unlimited use in the alternative medicine market today.
AMT's Research and Development operations are based in USA, Germany and Ukraine, and conducted through the lab in New York and clinical applications in Ukraine. AMT's management team consists of Dr. Boris Farber (CEO and Chairman of the Board), Dr. Evgenia Skobeltzin (Leading Scientist R&D), and Tatiana Skobeltzin (Administration Manager, Germany).
According to Dr. Farber, with our unique Blood Cell Morphometric Method, we will be able to provide new and effective technology to deal with early cancer detection in healthy individuals and monitor the treatment efficiency in patients diagnosed with cancer. This will revolutionize the field of oncology and may become a new standard of care in this $219.2 billion market.
In additional news, Mr. Larry Skolnik, President of MEDITOR and Dr. Boris Farber, CEO and Chairman of AMT are continuing to develop relationships with market makers in Europe to help create additional investor awareness of Meditor and AMT on the Frankfurt and Berlin Exchanges.
The company's first stop on its investor relations tour will be in Munich this Monday 16 March 2009 at Hotel Le Meridien in the Elysee II Suite.
This release may contain certain "forward-looking statements" with respect to certain of Indenture Investments Ltd's plans and its current goals and expectations relating to its future financial condition, performance, results, strategy and objectives. Statements containing the words "believes", "intends", "expects", "plans", "seeks" and "anticipates", and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond Indenture Investments Ltd's control including among other things, Canadian domestic and global economic and business conditions, market related risks, and the performance of financial markets generally; the policies and actions of regulatory authorities, the impact of competition, inflation, and deflation; the timing, impact and other uncertainties of future acquisitions or combinations within relevant industries; and the impact of changes in capital, solvency or accounting standards, and tax and other legislation and regulations in the jurisdictions in which Indenture Investments Ltd. operates. As a result, Indenture Investments Ltd's actual future financial condition, performance and results may differ materially from the plans, goals, and expectations set forth in Indenture Investments Ltd's forward-looking statements. Indenture Investments Ltd. undertakes no obligation to update the forward-looking statements contained in this section or any other forward-looking statements it may make.
|SOURCE Meditor Pharmaceuticals Ltd.|
Copyright©2009 PR Newswire.
All rights reserved